L19: AML + MDS notes:
	- leukemogenesis: decreased differentiation + increased proliferation
	- AML risks:
		- topoIIi (del 11q23) + akylators (del 5+7)
		- radiation/solvents
		- downs, li fraumeni (p53), fanconi's anemia
	- Sx: bleeding/bruising/ecchymoses/petechiae, hepatosplenomegaly, dyspea etc
	- bad muts: tp53, SF3B1, inv(3), BCR-ABL1
	- intermediate muts: FLT3, t(9, 11), 
	- good muts: t(8, 21), inv(16), NPM1 w/o FLT3
	- therapy:
		- 7+3, SCT
		- gemtuzumab: CD33
		- FLT3 muts: midostaurin, gilteritinib
	- induction -> aplasia -> infections
	- paradigm:
		- low risk t(8, 21), inv(16): 7+3
		- high risk: allo SCT
		- med risk: if donor -> allo sct
		- old/weak -> venetoclax
	- median age ~70

	- APL: 
		- 10% AML,
		- bleeding diathesis
		- t(15, 17)
		- use ATRA + arsenic
		- APL differentiation syndrome
			- early: fever, dyspnea, weight gain
			- late: pulm infiltrates, pleural/pericardial effusions
			- use steroids
			- 30% of APL during induction
	- MDS:
		- BM + PM blasts < 20%
		- IPSS-R scoring: uses cyto, BM blast %, ANC, platelets, hemoglobin
		- 5q- syndrome:
			- more female
			- mild, anemia + thrombocytosis
			- mild neutropenia
			- tx: lenalidomide
		- tx:
			- young MDS -> allo SCt
			- no HLA, stable -> supportive + low tox therapy
			- no HLA, young or progressive -> low: lenalidomide, high: hypomethylators or AML induction
			- ring-sideroblasts -> luspatercept



L20 ALL + CLL:
	- ALL:
		- rare, mostly kids
		- worse prognosis:
			- older
			- t(9, 22)
			- T-cell phenotype
			- MRD
		- good prognosis:
			- t(12, 21)
		- risks: radiation, downs
		- symptoms:
			- bleeding
			- effective neutropenia
			- fatigue, dyspnea, dizziness
			- fever, bone pain, CNS symptoms
			- ecchymoses, petechiae
			- splenomegaly
		- T cell - ALL: mediastinal mass, SVC-like syndrome
		- pathology:
			- large and sticky pull apart bread
			- open chromatin
			- light purple cytoplasm
			- no granules

		- markers:
			- TdT+: blast
			- CD10: B-cell lymphoblast

		- tumor lysis syndrome:
			- all up (phos, urea, K+)
			- Ca+ down (phos soaks up)
			- tx: allopurinol, rasburicase, hydration
		- tx:
			- relapse -> allo SCT

	- CLL:
		- most common adult leukemia
		- median age ~70
		- 1/3 no tx, 1/3 deferred tx
		- richter transformation: rare transform to DLBCL
		- mutatated IGHV -> more differentiated -> better prognosis
		- pathology:
			- smudge cells
			- soccer ball look
			- Crushed Little Lymphocytes

		- presentation:
			- lymphocytosis
			- lymphadenopathy
			- cytopenia symptoms
			- splenomegaly + weight loss

		- markers:
			- CD5, CD19/20/23

		- staging:
			- 0: >5000/ul monoclonal lymphocytosis + markers
			- 1: lymphadenopathy
			- 2: splenomegaly
			- 3: hemoglobin < 11
			- 4: platelets < 100k
		- prognosis:
			- good: 13q-
			- bad: 17p-
		- symptoms:
			- ITP
			- AIHA (autoimmune hemolytic anemia)
			- hypogammaglobilenmia
			- pure red cell aplasia (PRCA)

		- tx:
			- treat stage 3/4 or symptomatic
			- FCR/ibrutinib/venetoclax



L21 B-cell lymphoma:
	- evaluation:
		 - CBC, LDH, viral serologies, LP if CNS, BM biopsy
		 - biopsy node

	- lugano staging:
		- I: one sided same half
		- II: multiple same half
		- III: multiple two halves
		- organ involvement

	- prognosis:
		- IPI: age, ECOG, LDH, # extra-nodal sites, stage

	- non-hodgkins:
		- symptoms:
			- lymphadenopathy
			- splenomegaly
			- CNS
			- cytopenias
			- B symptoms: constitutional symptoms + drenching night sweats


	- diffuse large N cell lymphoma:
		- germinal center
		- prognosis:
			- aggressive
			- fatal within months
			- 65% cure rate
		- associated with HIV
		- pathology:
			- 4-5x size of lymphocyte
			- diffuse growth pattern
			- markers: CD19+, CD20+
		- tx:
			- pol R-CHOP, outpatient
			- rituximab:
				- can reactivate HBV: use prophylaxis if HBV+
				- hypogammaglobulinemia
				- progressive multifocal leukoencephalopathy (PML)
					- demyelinating -> often fatal
					- JC virus
			- relapse: CAR-T
		- primary CNS:
			- ring enhancing lesion
			- AIDS-defining illness
			- HIV/EBV associated
			- tx: methotrexate +

	- burkitt's lymphoma:
		- germinal center
		- course: rapid englargement in days
		- pathogenesis:
			- c-myc translocation with heavy chain Ig, t(8, 14)
			- fastest lymphoma, Ki67 ~100%
		- pathology: CD20+ starry sky, tingible body macrophages
		- types:
			- HIV associated:
				- 25% latent EBV
			- african endemic:
				- 100% EBV
				- location:
					- mandible
					- abdominal viscera
					- kidneys
					- ovaries
					- adrenals
			- sporadic:
				- 20% latent EBV
				- leocecum + peritoneum
		- tx: intense chemo

	- mantle cell lymphoma:
		- aggresive:
		- pathology:
			- small lymphocytes
			- nodular to diffuse
			- markers: cyclin D1+, CD20+
			- t(11, 14): cyclin D1:IgH
		- tx:
			- cytarabine + auto-SCT
			- if weak: bendamustine + RCT

	- follicular lymphoma:
		- sx:
			- asymptomatic lymphadenopathy
		- pathology:
			- nodular pattern
			- looks like follicles but denser
			- markers: BCL2+, CD20+

		- pathogenesis:
			- t(14, 18): IgH + BCL-2
		- tx:
			- stage I: radiation
			- low burden: rituximab
			- high burden: B-CHOP
			- relapse: car-T

	- marginal zone lymphoma:
		- pathogenesis:
			- infection: stomach - H. pylori
				- CagA+ strains
			- auto-antigen: salivary gland - sjogren syndrome
			- t(11, 18): API2/MALT1
		- pathology:
			- MALT lymphoma




L23 Hodgkins + T cell lymphoma:
	- hodgkins:
		- CD20- B-cell lymphoma
		- pathology:
			- reed-sternberg (RS) cells
				- binucleate owl's eyes: hoot for hodgkins
			- RS cells <10%
			- background of macrophages + eosinophils
			- markers: CD30+, CD15+, EBV+, 
		- pathogenesis:
			- derive from GC B-cells
				- no IgG production or hypermutation
			- spread through lymph contiguously
		- types:
			- nodular sclerosis: most common
			- mixed cellularity: HIV, eosinophilia
			- lymphocyte rich: best prognosis
			- lymphocyte depleted: worst prognosis
		
		- epidimiology:
			- bimodal ages: mainly young

		- presentation:
			- large mediastinal mass
			- B symptoms
			- pruritus
			- pel ebstein fevers
			- painful nodes with EtOH

		- staging (use PET/CT):
			- 1: same side
			- 2: >3
			- 3: nodes above and below diaphram
			- 4: infiltrates organs
			- A: no constitutional sx
			- B: fever, night sweats, >=10% wt loss

		- prognosis:
			- I-II: 90% cure rate
			- III-IV: 75% cure rate
			- B symptoms worse

		- tx: A + AVD, etc, allo transplant, anti-pd1, BV


	- T-cell lymphoma:
		- rare/heterogenous
		- staging: like non-hodgkins B-cell

		- cutaneous T cell lymphoma (mycosis fungoides):
			- indolent
			- risks: eczema
			- stages:
				- patch-plaque stage
				- tumor
				- lymph node involvement
				- sezary syndrome: leukemic involvement

			- pathology:
				- Pautrier microabscess: intraepidermal neoplastic cell aggregates
				- sezary cell: CD4+ + "cerebriform nuclei"

		- peripheral T cell lymphoma: PTCL-NOS:
			- collector diagnosis
			- tx:
				- etoposide, gemcitabine
				- remission -> transplant

		- anaplastic large T cell lymphoma:
			- ALK+: younger, t(2, 5) -> better prognosis
			- tx: CD30+ so use BV
			- pathology: horeshoe shaped nuclei

		- HTLV-1 / adult T-cell leukemia/lymphoma (ATLL):
			- pathology: flower cell
			- markers: CD4+, CD25+, sometimes CD30+
			- pathogeneis:
				- driven by HTLV-1
				- long latency
			- epidimiology:
				- endemic to africa, japan, and caribbean
			- sx:
				- hypercalcemia
				- lytic bone lesions
				- CNS lesions
				- rash
				- lymphadenopathy


L24 multiple myeloma:
	- multiple myeloma:
		- epidimiology
			- 2nd most commmon heme malignancy
			- median age ~70
			- ~5 year survival
			- 2x in blacks, more in men
			- blacks better surival
		- pathology:
			- plasma cell cancer
			- fried egg cell with light golgi "clockface" nuclei
			- rouleaux formation RBCs
		- secrete M proteins:
			- detect with SPEP/UPEP: look for M-spike > 3
			- serum immunofixation (SIFE): identify heavy chain (G, A, or M) + light chain (κ or λ)
			- IgG most common
			- light chain mainly detected by urine or lambda:kappa ratio

		- presentation:
			- CRAB
				- hyperCalcemia
				- Renal insufficiency
				- Anemia
				- Bone Pain
				- constitutional symptoms
		- dx:
			- need 1 and 2/3
			- 1a: BM biopsy: >= 10% clonal plasma cells or
			- 1b: plasmacytoma
			- 2: end organ damage: >=1 CRAB Sx
			- 3: myeloma biomarker"
				- BM >= 60% clonal plasma cells
				- MRI > 1 bone lesion
				- kappa:lambda ratio >= 100

		- dx/monitoring:
			- CBC
			- albumin, LDH, β2-microglobulin
			- imaging: PET/CT

		- staging:
			- I: β2-M < 3.5 + albumin >= 3.5 + normal FISH/LDH
			- III: β2-M >= 5.5 + high-rish FISH or high LDH
			- II: not I or III

		- course:
			- active -> remission -> relapse -> repeat
		- tx:
			- allo transplant + SPI, SAI, or SI


	- monoclonal gammopathy of undetermined significance (MGUS):
		- pre-SMM/MM
		- 1% per yr -> MM
		- no significant features
		- tx: observe 6-12 mos

	– smoldering multiple myeloma (SMM):
		- M-spike > 3
		- BM clonal plasma >= 10%
		- 50% at 5 yr -> MM
		- observe every 3 months

	– waldenstrom’s macroglobulinemia:
		- rare
		- lymphoplasmacytic cells
		- MYD88 mutation
		- M protein: IgM
		- symptoms:
			- hyperviscosity: blurry vision, headache, vertigo, stroke, etc
			- oronasal bleeding
			- hepatosplenomegaly, lymphadenopathy
			- anemia, weakness
			- neuropathy
			- raynaud phenomenon

	– AL amyloidosis:
		- light chain unique:
			- plasma disorder: can be alongside myeloma
			- tx: chemo
		- extracellular deposits of amyloid fibrils
		- course: death from heart or renal deposits


L25 CML + NPMs:
	- CML:
		- 45-55 yo
		- slightly male
		- presentation:
			- incidental
			- constitutional symptoms
			- hepatosplenomegaly
			- ecchymoses
		- pathology:
			- basophilia, thrombocytosis
			- peripheral blood: looks like bone marrow
			- bone marrow: hypercellular, increased myeloid:erythroid
		- t(9, 22):
			- tons of things
		- phases:
			- chronic (4-6 years)
			- accelerated: variable
			- blast crisis:
				- 3-6 mo survival
				- either myeloid or lymphoid
		- tx: imatinib, nilotinib
			- complete response:
				- normal WBC, platelets, no immature cells
				- 0% t(9, 22) cells
				- > 4.5 log reduction BCR-ABL transcripts
			- partial response: 1-35% t(9, 22) cells
			- major response: >3 log reduction BCR-ABL transcripts
			- can stop meds if responded

	- polycythemia vera (PV):
		- high HGB/HCT
		- thrombosis
		- Sx:
			- pruritus: especially post shower
			- plethora
			- splenomegaly
			- fatigue

		- JAK2 V617F:
			- 95% of PV
			- EPO signaling uses JAK2 pathway -> increased RBCs

		- pathology:
			- bone marrow: moderate/marked hypercellularity
			- large clustered megakaryocytes
			- decreased iron stores
			- increased reticulin fibers
		- dx:
			- Hgb > 16.5 + HCT > 49%
			- BM biopsy: hypercellularity + pleomorphic mature megakaryocytes
			- JAK2 mutation
			- minor: low EPO

		- tx: phlebotomy, etc
		- 3% mortality each year
			- thrombosis/bleeding
			- transform to AML or PMF

	- essential thrombocytosis (ET):
		- presentation:
			- high platelets
			- thrombosis
			- puritus: especially post shower
			- erythromelalgia
			- splenomegaly
		- genetics:
			- 50% JAK2 V617F
			- 35% calreticulin muts: mut CALR activates MPl
			- 5% MPL (thrombopoetin receptor)

		- dx:
			- platelet > 450 for 2+ months
			- BM biopsy: megakaryocyte proliferation
			- no evidence of CML, MDS, PV, or PMF
			- JAK2, CALR, or MPL mut
			- minor: clonal marker or no reactive thrombocytosis

		- tx:
			- low dose aspirin
			- etc
		- course:
			- thrombosis
			- 1% untreated -> AML
			- 4-8% -> PMF

	- primary myelofibrosis (PMF):
		- pathology:
			- BM fibrosis
			- bizarre megakaryocyte hyperplasia
			- extramedullary hematopoiesis
				- in spleen, liver, etc
			- teardrop RBCs
			- blood looks like marrow	
		- presentation:
			- splenomegaly
			- anemia
			- bleeding/bruising
			- infection
			- cachexia
		- dx:
			- megakaryocyte atypia + reticulin fibers grade 2/3
			- no evidence of CML, PV, ET, or MDS
			- JAK2, CALR, MPL mut, other clone or no reactive fibrosis
			- minor:
				- leukocytos > 11
				- high LDH
				- splenomegaly
				- anemia
				- leukoerythroblastosis
			- all major + 1 minor

		- course:
			- life expectancy: variable ~5 years
			- risks:
				- age, Hgb < 10, WBC > 25, blasts > 1%
				- constitutional symptoms
				- inv(3), del 5/7, +8, del 11q23
				- platelets < 100
			- 10-15% -> AML

		- tx: supportive SETHS + active JITS